169 related articles for article (PubMed ID: 35588692)
1. Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.
Maio M; Amonkar MM; Norquist JM; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Wang R; Norwood K; Marabelle A
Eur J Cancer; 2022 Jul; 169():188-197. PubMed ID: 35588692
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Amonkar M; Yao L; Jin F; Norwood K; Maio M
Gynecol Oncol; 2022 Aug; 166(2):245-253. PubMed ID: 35835611
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
Maio M; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Xu L; Jin F; Norwood K; Marabelle A
Ann Oncol; 2022 Sep; 33(9):929-938. PubMed ID: 35680043
[TBL] [Abstract][Full Text] [Related]
5. Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629.
Hughes BGM; Mendoza RG; Basset-Seguin N; Vornicova O; Schachter J; Joshi A; Meyer N; Grange F; Piulats JM; Bauman JR; Chirovsky D; Zhang P; Gumuscu B; Swaby RF; Grob JJ
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1777-1790. PubMed ID: 34558040
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
11. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
Schmid P; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Mejia JA; Zhou X; Haiderali A; Nguyen AM; Cortes J; Winer EP
Eur J Cancer; 2023 Dec; 195():113393. PubMed ID: 37976633
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA; Luke JJ; Long GV; Ascierto PA; Rutkowski P; Schadendorf D; Robert C; Grob JJ; de la Cruz Merino L; Del Vecchio M; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Carlino MS; Mohr P; De Galitiis F; Ross MI; Eroglu Z; Chen K; Jiang R; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Kirkwood JM
Eur J Cancer; 2022 Nov; 176():207-217. PubMed ID: 36202690
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Van Cutsem E; Amonkar M; Fuchs CS; Alsina M; Özgüroğlu M; Bang YJ; Chung HC; Muro K; Goekkurt E; Benson AB; Sun W; Wainberg ZA; Norquist JM; Chen X; Shih CS; Shitara K
Gastric Cancer; 2021 Nov; 24(6):1330-1340. PubMed ID: 34363528
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
[TBL] [Abstract][Full Text] [Related]
16. Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Choueiri TK; Tomczak P; Park SH; Venugopal B; Symeonides S; Hajek J; Ferguson T; Chang YH; Lee JL; Haas N; Sawrycki P; Sarwar N; Gross-Goupil M; Thiery-Vuillemin A; Mahave M; Kimura G; Perini RF; Saretsky TL; Bhattacharya R; Xu L; Powles T
Oncologist; 2024 Feb; 29(2):142-150. PubMed ID: 37589219
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164.
Le DT; Diaz LA; Kim TW; Van Cutsem E; Geva R; Jäger D; Hara H; Burge M; O'Neil BH; Kavan P; Yoshino T; Guimbaud R; Taniguchi H; Élez E; Al-Batran SE; Boland PM; Cui Y; Leconte P; Marinello P; André T
Eur J Cancer; 2023 Jun; 186():185-195. PubMed ID: 37141828
[TBL] [Abstract][Full Text] [Related]
20. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS
J Thorac Oncol; 2019 May; 14(5):793-801. PubMed ID: 30711649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
